

## Claims

I claim:

A method of inhibiting the development of opioid tolerance by  
5 clinically administering a chemically combination of a  
pharmacologically active form of substance P with morphine in a  
chimeric hybrid molecule wherein morphine, chemically modified and  
covalently linked through its 6'OH group, comprises a cyclic  
alkaloid moiety which binds as an agonist to a mammalian or human  
10 mu ( $\mu$ ) opioid receptor; and wherein a pharmacologically active C-  
terminal substance P fragment, chemically modified and covalently  
linked through its free NH<sub>2</sub> group, comprises a peptide moiety  
which binds as an agonist to a mammalian/human substance P  
receptor; and wherein a compact, but flexible, molecular hinge  
15 covalently cross links morphine through its 6'OH group to the free  
NH<sub>2</sub> group of the substance P receptor agonist moiety, so as to  
allow both the mu ( $\mu$ ) opioid receptor and the substance P receptor  
agonist moieties to activate their respective receptors  
simultaneously and independently.